Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4033470 | 0.90 | KCNH2 (0.41) | ACHETP53KCNH2ACKR3GPR119 | |
| SCHEMBL4034511 | 0.88 | USP7 (0.45) | ACHETP53KCNH2ACKR3GPR119 | |
| SCHEMBL4031576 | 0.85 | ACHE (0.41) | ACHETP53KCNH2GPR119USP30 | |
| SCHEMBL4667317 | 0.77 | LMNA (0.44) | TP53KMT2AACKR3GPR119TBK1 | |
| Hydrochloric Acid SCHEMBL4668573 | 0.76 | LMNA (0.43) | TP53KMT2AACKR3GPR119TBK1 | |
| SCHEMBL14290077 | 0.75 | ACHE (0.48) | ACHETP53GPR119USP30OPRK1 | |
| SCHEMBL5211298 | 0.71 | USP30 (0.42) | ACHETP53KCNH2GPR119USP30 | |
| SCHEMBL4033859 | 0.71 | CNR2 (0.41) | OPRK1OPRM1 | |
| Hydrochloric Acid SCHEMBL5215563 | 0.70 | USP30 (0.41) | ACHETP53KCNH2GPR119USP30 | |
| SCHEMBL5210559 | 0.70 | S1PR1 (0.43) | ACHETP53GPR119USP30OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | claimed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | DRD2, DRD4, PNMT | ACHE 72/4885TP53 4824/4885KCNH2 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.